April 9, 2018 / 6:36 AM / 4 months ago

BRIEF-Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies

April 9(Reuters) - Takara Bio Inc

* Says it has entered into an agreement with Otsuka Pharmaceutical Co., Ltd for co-development and exclusive sales rights in Japan for Takara’s NY-ESO-1 siTCRTM (TBI-1301, TBI-1301-A) and CD19 CAR (TBI-1501) gene therapies

Source text in Japanese:goo.gl/YzGkkU

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below